Document Detail

Octreotide long-acting release (LAR): a review of its use in the management of acromegaly.
MedLine Citation:
PMID:  20731479     Owner:  NLM     Status:  MEDLINE    
Octreotide long-acting release (LAR) [Sandostatin LAR] is a somatostatin analogue with a well established clinical profile in patients with acromegaly. It binds to somatostatin receptor subtypes 2 and 5 with high potency to reduce the production and secretion of growth hormone (GH) and insulin-like growth factor (IGF)-I. Octreotide LAR is administered intramuscularly once every 28 days, in contrast to the subcutaneous formulation which requires administration two to three times daily. In several noncomparative trials, octreotide LAR was effective as primary therapy in normalizing GH and IGF-I levels and reducing tumour volume in patients with acromegaly. In addition, no significant difference was seen between octreotide LAR and surgery or lanreotide long-acting (LA) or lanreotide Autogel(R) (ATG) in small, randomized or observational, primary therapy trials. In another small, randomized trial, preoperative octreotide LAR followed by surgery was no more effective than surgery alone in terms of normalizing IGF-I levels, except in patients with macroadenoma. Octreotide LAR has also demonstrated good efficacy as postoperative adjuvant therapy, alone or in combination with pegvisomant, in randomized or noncomparative trials. In patients with different treatment histories (mixed populations), the efficacy of octreotide LAR appears to be generally similar to that of lanreotide ATG and greater than that of lanreotide LA, according to data from switching or crossover studies. Also in mixed populations, the efficacy of octreotide LAR was not significantly different to that of pegvisomant in terms of normalizing IGF-I levels in a randomized trial, and octreotide LAR demonstrated good efficacy in combination with cabergoline in a small, sequential-treatment trial. Octreotide LAR was generally well tolerated in clinical trials, with the most commonly occurring adverse events being gastrointestinal or hepatobiliary in nature. Thus, octreotide LAR continues to be a valuable option in the treatment of acromegaly.
Lily P H Yang; Gillian M Keating
Related Documents :
17681999 - A prospective randomised study on narrow-band imaging versus conventional colonoscopy f...
14674719 - The treatment of de novo acromegalic patients with octreotide-lar: efficacy, tolerabili...
24047869 - Racial disparities in knee and hip total joint arthroplasty: an 18-year analysis of nat...
17457209 - Long-term follow-up of free-floating epithelial inclusion cyst after radial keratotomy.
6594009 - Danazol treatment of severely symptomatic fibrocystic breast disease and long-term foll...
11081189 - Efficacy of combined treatment with lanreotide and cabergoline in selected therapy-resi...
24114669 - Outcome with immediate direct anastomosis of recurrent laryngeal nerves injured during ...
3339039 - Reconstruction for chronic anterior cruciate instability. a comparison of two methods a...
17011899 - Laparoscopic gastric bypass: risks vs. benefits up to two years following surgery in su...
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Drugs     Volume:  70     ISSN:  0012-6667     ISO Abbreviation:  Drugs     Publication Date:  2010 Sep 
Date Detail:
Created Date:  2010-08-24     Completed Date:  2010-12-02     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  7600076     Medline TA:  Drugs     Country:  New Zealand    
Other Details:
Languages:  eng     Pagination:  1745-69     Citation Subset:  IM    
Adis, a Wolters Kluwer Business, Auckland, New Zealand.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Acromegaly / drug therapy*,  pathology
Antineoplastic Agents, Hormonal / administration & dosage,  pharmacokinetics,  therapeutic use*
Clinical Trials as Topic
Delayed-Action Preparations
Human Growth Hormone / antagonists & inhibitors,  secretion
Insulin-Like Growth Factor I / antagonists & inhibitors,  secretion
Octreotide / administration & dosage,  pharmacokinetics,  therapeutic use*
Receptors, Somatostatin / metabolism
Reg. No./Substance:
0/Antineoplastic Agents, Hormonal; 0/Delayed-Action Preparations; 0/Receptors, Somatostatin; 0/somatostatin receptor 2; 0/somatostatin receptor 5; 12629-01-5/Human Growth Hormone; 67763-96-6/Insulin-Like Growth Factor I; 83150-76-9/Octreotide

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Tapentadol immediate release: a review of its use in the treatment of moderate to severe acute pain.
Next Document:  Bariatric surgery in wome of reproductive age: special concerns for pregnancy.